ADVENT TECHNOLOGIES HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADVENT TECHNOLOGIES HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.28M | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | $1.54M | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.84M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $7.07M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $731.9K | Mar 31, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.28M | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | $1.51M | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | $1.26M | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | $1.11M | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | $977.0K | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | $1.96M | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | $2.40M | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | $2.23M | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | $1.26M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.90M | Mar 31, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.79M | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | ($10.94M) | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | ($1.19M) | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | ($793.0K) | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | ($507.0K) | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | ($498.0K) | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | $60.0K | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | ($45.0K) | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | ($261.0K) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $159.0K | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($40.99M) | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | ($25.73M) | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | ($11.85M) | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | ($21.83M) | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | ($11.99M) | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | ($47.63M) | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | ($11.47M) | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | ($11.15M) | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | ($4.10M) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | ($9.01M) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($18.37M) | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | ($25.70M) | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | ($11.66M) | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | ($21.29M) | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | ($11.70M) | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | ($50.08M) | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | ($11.09M) | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | ($11.15M) | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | ($13.10M) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | ($16.66M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.23M | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | $3.96M | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | $2.13M | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | $2.88M | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | $3.14M | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | $2.46M | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | $2.55M | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | $2.64M | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | $2.15M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $1.98M | Mar 31, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.32M | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | $6.73M | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | $8.92M | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | $8.33M | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | $8.49M | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | $9.26M | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | $8.20M | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | $7.96M | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | $10.50M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $14.32M | Mar 31, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.40M | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | ($20.98M) | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | ($32.13M) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | ($35.84M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.43M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($630.9K) | May 20, 2021 |
| FY2019 | Dec 31, 2018 | ($114.1K) | Mar 27, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.01M | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | $34.74M | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | $89.59M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $163.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.89M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $226.01M | May 20, 2021 |
| FY2019 | Dec 31, 2018 | $222.08M | Mar 27, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $29.30M | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | $21.29M | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | $25.44M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $32.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.69M | Mar 31, 2022 |
| FY2020 | Sep 30, 2020 | $31.56M | May 20, 2021 |
| FY2020 | Jun 30, 2020 | $24.85M | May 20, 2021 |
| FY2020 | Mar 31, 2020 | $14.67M | May 20, 2021 |
| FY2020 | Dec 31, 2019 | $19.25M | May 20, 2021 |
| FY2020 | Sep 30, 2019 | $19.57M | May 20, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($21.30M) | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | $13.45M | Jun 6, 2025 |
| FY2024 | Dec 31, 2022 | $64.15M | Jun 6, 2025 |
| FY2023 | Dec 31, 2021 | $130.20M | Aug 13, 2024 |
| FY2022 | Dec 31, 2020 | ($1.79M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($833.8K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $5.00M | May 20, 2021 |
| FY2019 | Jun 17, 2018 | $0 | Mar 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $5.74M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $30.03M | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | $29.40M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($220.15M) | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | ($179.16M) | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | ($107.76M) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | ($33.43M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($12.90M) | Mar 31, 2022 |
| FY2020 | Sep 30, 2020 | $8.42M | May 20, 2021 |
| FY2020 | Jun 30, 2020 | $14.18M | May 20, 2021 |
| FY2020 | Mar 31, 2020 | $25.18M | May 20, 2021 |
| FY2020 | Dec 31, 2019 | $20.23M | May 20, 2021 |
| FY2020 | Sep 30, 2019 | $19.05M | May 20, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $381.0K | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | $3.20M | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | $32.87M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | $79.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $515.7K | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (15) | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | (12) | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | (5) | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | (12) | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | (6) | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | (27) | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | (6) | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | (6) | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (15) | Jun 6, 2025 |
| FY2023 | Dec 31, 2023 | (12) | Aug 13, 2024 |
| FY2023 | Sep 30, 2023 | (5) | Aug 13, 2024 |
| FY2023 | Jun 30, 2023 | (12) | Aug 13, 2024 |
| FY2023 | Mar 31, 2023 | (6) | Aug 13, 2024 |
| FY2023 | Dec 31, 2022 | (27) | Aug 13, 2024 |
| FY2023 | Sep 30, 2022 | (6) | Aug 13, 2024 |
| FY2023 | Jun 30, 2022 | (6) | Aug 13, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2.64M | Jun 6, 2025 |
| FY2024 | Dec 31, 2023 | 2.58M | Jun 6, 2025 |
| FY2023 | Dec 31, 2022 | 1.72M | Aug 13, 2024 |
| FY2022 | Dec 31, 2021 | 51.25M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 25.03M | Mar 31, 2022 |